Author:
Cascio Vincent,Gittings Daniel,Merloni Kristen,Hurton Matthew,Laprade David,Austriaco Nicanor
Abstract
Abstract
Background
Saccharomyces boulardii is a probiotic yeast routinely used to prevent and to treat gastrointestinal disorders, including the antibiotic-associated diarrhea caused by Clostridium difficile infections. However, only 1-3% of the yeast administered orally is recovered alive in the feces suggesting that this yeast is unable to survive the acidic environment of the gastrointestinal tract.
Results
We provide evidence that suggests that S. boulardii undergoes programmed cell death (PCD) in acidic environments, which is accompanied by the generation of reactive oxygen species and the appearance of caspase-like activity. To better understand the mechanism of cell death at the molecular level, we generated microarray gene expression profiles of S. boulardii cells cultured in an acidic environment. Significantly, functional annotation revealed that the up-regulated genes were significantly over-represented in cell death pathways Finally, we show that S-adenosyl-L-methionine (AdoMet), a commercially available, FDA-approved dietary supplement, enhances the viability of S. boulardii in acidic environments, most likely by preventing programmed cell death.
Conclusions
In toto, given the observation that many of the proven health benefits of S. boulardii are dependent on cell viability, our data suggests that taking S. boulardii and AdoMet together may be a more effective treatment for gastrointestinal disorders than taking the probiotic yeast alone.
Publisher
Springer Science and Business Media LLC
Subject
Microbiology (medical),Microbiology
Reference50 articles.
1. FAO/WHO: Guidelines for the Evaluation of Probitics in Food. 2002, Food and Agriculture Organization of the United Nations: In. London Ontario, Canada: World Health Organization
2. Gismondo MR, Drago L, Lombardi A: Review of probiotics available to modify gastrointestinal flora. Int J Antimicrob Agents. 1999, 12 (4): 287-292. 10.1016/S0924-8579(99)00050-3.
3. McCullough MJ, Clemons KV, McCusker JH, Stevens DA: Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol. 1998, 36 (9): 2613-2617.
4. Htwe K, Yee KS, Tin M, Vandenplas Y: Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008, 78 (2): 214-216.
5. McFarland LV: Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 2007, 5 (2): 97-105. 10.1016/j.tmaid.2005.10.003.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献